Triptorelin is a synthetic GnRH agonist, engineered from native GnRH for far greater potency and duration than gonadorelin. Instead of stimulating the reproductive axis, sustained exposure suppresses it, downregulating pituitary GnRH receptors after a brief initial “flare.” It is FDA-approved as Trelstar, Decapeptyl and Triptodur for advanced prostate cancer and central precocious puberty, with decades of Phase 3 evidence, one of the more mature evidence bases of any compound this site covers. Its mechanism is deliberate suppression of sex hormone production, the pharmacological opposite of the hormone-optimization use it is sometimes discussed for in research-peptide circles.
Ask about Triptorelin
Research snapshot
| Category | Current information |
|---|---|
| Peptide category | GnRH agonist (synthetic decapeptide) |
| Primary research interest | Sex-hormone suppression: advanced prostate cancer; central precocious puberty; endometriosis/fibroids (outside US) |
| Highest available evidence | Tier 1 – decades of Phase 3 trials and long-term outcome data |
| Human research available | Yes, extensive – one of the more mature evidence bases of any compound on this site |
| Development status | Approved (Trelstar, Decapeptyl, Triptodur, Diphereline) |
| Regulatory status | FDA-approved for advanced prostate cancer and central precocious puberty; approved elsewhere for endometriosis and uterine fibroids |
Technical identity
| Technical property | Information |
|---|---|
| Primary name | Triptorelin |
| Alternative names | Trelstar, Decapeptyl, Triptodur, Diphereline (brand names) |
| Peptide sequence | Synthetic decapeptide analogue of native GnRH, engineered for greater potency and duration than gonadorelin |
| Amino-acid length | 10 residues |
| Molecular formula | C64H82N18O13 |
| Molecular weight | 1311.47 g/mol |
| CAS Registry Number | 57773-63-4 |
| PubChem CID | 25074470 |
| Chemical modifications | Amino acid substitutions relative to native GnRH for resistance to enzymatic degradation and enhanced receptor binding |
| Peptide class | GnRH agonist |
| Primary biological target | Pituitary GnRH receptor (downregulation/desensitization on sustained exposure) |
| Developer or originator | Multiple manufacturers under various brand names (Debiopharm/Ipsen among others) |
| Development status | FDA-approved; approved in additional jurisdictions for further indications |
What it is
Triptorelin is a synthetic GnRH agonist, a modified decapeptide analogue of native GnRH engineered for much greater potency and a longer duration of action than gonadorelin. Rather than stimulating the reproductive axis the way pulsatile native GnRH does, sustained triptorelin exposure downregulates and desensitizes pituitary GnRH receptors, producing a profound, reversible suppression of LH, FSH and downstream sex steroids after an initial transient stimulation (“flare”) in the first one to two weeks of treatment.
It is FDA-approved, sold under brand names including Trelstar, Decapeptyl and Triptodur, for advanced prostate cancer (as a form of medical castration), central precocious puberty in children, and, outside the US, endometriosis and uterine fibroids. It is given as an intramuscular depot injection, in monthly, 3-month or 6-month long-acting formulations depending on the product.
What dosage information circulates?
Figures in this table summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| Advanced prostate cancer (approved) | Intramuscular depot | Per FDA label (varies by depot formulation) | Monthly, every 3 months, or every 6 months depending on product | Ongoing/chronic | FDA-approved prescribing information |
| Central precocious puberty (approved) | Intramuscular depot | Per FDA label (Triptodur) | Every 6 months | Ongoing, per physician monitoring | FDA-approved prescribing information |
| General hormonal manipulation, non-approved | Intramuscular or subcutaneous | Varies by listing | Varies by listing | Varies by listing | Community / vendor reported |
No trial reviewed for this entry tested any regimen for a wellness or hormone-optimization purpose, and the drug’s intended effect – suppressing sex hormones – is the opposite of what such use would be seeking.
Potential benefits and research applications
Medical castration in advanced prostate cancer, a mature, decades-old approved use
Triptorelin suppresses testosterone to castrate levels, a standard hormonal therapy for advanced prostate cancer, established across decades of Phase 3 trials and long-term outcome data.
Evidence: has been shown extensively in human Phase 3 trials and long-term clinical use (Tier 1, published human clinical evidence, FDA-approved indication).
Halting central precocious puberty in children, a second mature approved use
By suppressing the same hypothalamic-pituitary-gonadal axis, triptorelin halts early pubertal development in children with central precocious puberty, approved as Triptodur based on dedicated pediatric trial data.
Evidence: has been shown in human clinical trials (Tier 1, published human clinical evidence, FDA-approved pediatric indication).
Endometriosis and uterine fibroids, approved outside the US
Sustained hormone suppression is also used to manage endometriosis and uterine fibroids by reducing estrogen-driven tissue growth, an approved indication in jurisdictions outside the US.
Evidence: has been shown in human clinical trials supporting approval outside the US (Tier 1, published human clinical evidence); not an FDA-approved indication in the United States.
Anti-aging and hormone optimization, a use that contradicts the drug’s own mechanism
Triptorelin is sometimes discussed in research-peptide communities for anti-aging or general hormone optimization. Its approved mechanism is deliberate, sustained suppression of sex hormone production, the pharmacological opposite of what an optimization goal would seek.
Evidence: has not been established. No trial reviewed for this entry supports repurposing triptorelin for anti-aging, longevity or hormone-optimization use, and its mechanism argues directly against that use case.
The evidence behind its approvals
Triptorelin’s prostate cancer and precocious puberty indications rest on a substantial body of Phase 3 trial and long-term outcome data spanning decades, evaluating testosterone (or estradiol) suppression to castrate levels, disease-specific outcomes, and safety in each population, and this is one of the more mature evidence bases of any compound on this site.
What is not established for uses outside its approvals
Any use of triptorelin for anti-aging, longevity, or general hormone-optimization purposes, which is how it is sometimes discussed in the research-peptide community. Its approved mechanism is deliberate, sustained suppression of sex hormone production, the pharmacological opposite of a hormone-optimization goal, and no trial reviewed for this entry supports repurposing it that way.
Reversibility timelines and long-term effects when a GnRH agonist like triptorelin is used outside its approved dosing schedule or populations.
Frequently asked questions
What is triptorelin?
Triptorelin is a synthetic GnRH agonist, an FDA-approved decapeptide analogue of native GnRH used to suppress sex hormone production, sold as Trelstar, Decapeptyl and Triptodur.
How does triptorelin work?
Sustained exposure downregulates and desensitizes pituitary GnRH receptors, producing profound, reversible suppression of LH, FSH and downstream sex steroids, after a brief initial stimulatory “flare” in the first one to two weeks.
What dosage has been studied in humans?
Approved dosing is a depot intramuscular injection, given monthly, every 3 months or every 6 months depending on the product, studied across decades of Phase 3 trials for prostate cancer and precocious puberty.
What dosage commonly circulates online?
Circulating discussion for non-approved hormonal-manipulation purposes describes varying doses. No trial reviewed for this entry tested any regimen for that purpose, and it directly contradicts the drug’s intended suppressive effect.
Has triptorelin been studied in humans?
Yes, extensively, across decades of Phase 3 trials for its approved indications, one of the more mature evidence bases of any compound this site covers.
Is triptorelin approved for use?
Yes, in the US for advanced prostate cancer and central precocious puberty, and in other jurisdictions for endometriosis and uterine fibroids as well.
What routes of administration are reported?
It is given as an intramuscular depot injection in long-acting monthly, 3-month or 6-month formulations.
Can triptorelin be used for anti-aging or hormone optimization?
This has not been established, and its own approved mechanism argues against it. Triptorelin is designed to suppress sex hormone production, the opposite of what a hormone-optimization goal would want.
What side effects have been reported?
Effects consistent with sex-hormone suppression are expected and documented across its decades of approved use, including menopause-like symptoms and an initial stimulatory flare in the first one to two weeks.
What remains unknown about triptorelin?
Reversibility timelines and long-term effects when used outside its approved dosing schedule or populations, and any legitimate use for anti-aging, longevity or hormone-optimization purposes, which no trial supports.
Bottom line
Triptorelin is a mature, heavily studied, FDA-approved drug for suppressing sex hormone production, with decades of Phase 3 evidence behind its prostate cancer and precocious puberty indications. Its discussion in research-peptide communities as a hormone-optimization or anti-aging tool runs directly against its own established mechanism, and no trial reviewed for this entry supports that repurposing.
Related entries: hCG, human chorionic gonadotropin.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| General hormonal manipulation, non-approved | Intramuscular or subcutaneous | Varies by listing | Varies by listing | Varies by listing |
Circulating discussion of triptorelin outside its approved indications describes varying doses for non-approved hormonal-manipulation purposes. The approved dosing (depot IM injection, monthly to 6-monthly, for suppression to castrate hormone levels) was studied for prostate cancer and precocious puberty specifically; no trial reviewed for this entry tested any other regimen for a wellness or optimization purpose, and the drug's intended effect, suppressing sex hormones, is the opposite of what such use would be seeking.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Sources
- US Food and Drug Administration. TRELSTAR (triptorelin pamoate), prescribing information. Approved indication: advanced prostate cancer. FDA NDA 020715
- US Food and Drug Administration. TRIPTODUR (triptorelin), prescribing information. Approved indication: central precocious puberty in children. FDA NDA 209275
Compare Triptorelin with related compounds
Research area: Sexual health and melanocortin.